CLINICAL TRIALS PROFILE FOR EVOLOCUMAB

All Clinical Trials for evolocumab

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01375764 ↗	Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects	Completed	Amgen	Phase 2	2011-07-28	The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia unable to tolerate an effective dose of a statin.
NCT01375777 ↗	Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels	Completed	Amgen	Phase 2	2011-07-06	The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on the percent change from baseline in LDL-C when used as monotherapy in adults with hypercholesterolemia.
NCT01516879 ↗	Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study	Completed	Amgen	Phase 3	2012-01-05	To evaluate the efficacy, safety, and tolerability of 52 weeks of subcutaneous (SC) evolocumab (AMG 145) compared with placebo when added to assigned background lipid-lowering therapy.
NCT01588496 ↗	Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities	Completed	Amgen	Phase 2/Phase 3	2012-04-05	A study to determine the safety, tolerability, and efficacy of evolocumab (AMG 145) in patients with homozygous familial hypercholesterolemia (HoFH).
NCT01763827 ↗	Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2	Completed	Amgen	Phase 3	2013-01-21	The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneous (SC) monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with a 10-year Framingham risk score of 10% or less.
NCT01763866 ↗	LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2	Completed	Amgen	Phase 3	2013-01-15	The primary objective was to evaluate the effect of 12 weeks of evolocumab administered subcutaneously every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin, compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia.

Clinical Trial Conditions for evolocumab

Condition Name

Condition Name for evolocumab
Intervention	Trials
Hypercholesterolemia	9
Hyperlipidemia	8
Acute Coronary Syndrome	7
Coronary Artery Disease	5

Condition MeSH

Condition MeSH for evolocumab
Intervention	Trials
Hypercholesterolemia	20
Hyperlipidemias	19
Dyslipidemias	15
Hyperlipoproteinemias	10

Clinical Trial Locations for evolocumab

Trials by Country

Trials by Country for evolocumab
Location	Trials
United States	413
Japan	93
Canada	89
Australia	64
China	61

Trials by US State

Trials by US State for evolocumab
Location	Trials
New York	24
Ohio	21
California	20
Florida	16
North Carolina	15

Clinical Trial Progress for evolocumab

Clinical Trial Phase

Clinical Trial Phase for evolocumab
Clinical Trial Phase	Trials
Phase 4	34
Phase 3	32
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for evolocumab
Clinical Trial Phase	Trials
Recruiting	39
Completed	29
Not yet recruiting	13

Clinical Trial Sponsors for evolocumab

Sponsor Name

Sponsor Name for evolocumab
Sponsor	Trials
Amgen	43
NYU Langone Health	3
Johns Hopkins University	3

Sponsor Type

Sponsor Type for evolocumab
Sponsor	Trials
Other	98
Industry	52
NIH	2